01—Abstract
Summary
Summary of the 10-Q filed November 7, 2024. Cited figures are marked; the original filing is the authoritative source.
McKesson Corporation reported its financial results for the second quarter and first half of fiscal year 2025.
Total revenues saw a significant increase of 21% for the quarter and 14% for the six-month period, driven by growth in the U.S. Pharmaceutical segment and increased pharmaceutical distribution volumes internationally. However, diluted earnings per share decreased substantially, reflecting higher operating expenses and specific charges. Key items impacting the results include a substantial charge of $643 milliona related to the remeasurement of the Canadian retail disposal group to fair value less costs to sell.
Additionally, the company incurred $227 millionb in restructuring charges for enterprise-wide technology modernization initiatives. The company also continues to manage its significant estimated liability for opioid-related claims, totaling $6.4 billion as of period end.
Despite the earnings decline, McKesson demonstrated strong operational cash flow and continued to return capital to shareholders through share repurchases ($2.0 billionc in the first half) and a raised quarterly dividend. The company also announced a significant acquisition in the oncology sector, pending regulatory approval.
02—Key points
Key Highlights
- Revenue increased by 21% year-over-year to $93.7 billion for the quarter and 14% to $172.9 billion for the six months, primarily driven by the U.S. Pharmaceutical segment and international operations.
- Diluted earnings per share declined significantly to $1.87 for the quarter (down from $4.92) and $8.89 for the six months (down from $11.95), reflecting higher operating expenses and specific charges.
- The company recorded a $643 million charge related to the remeasurement of its Canadian retail disposal group to fair value less costs to sell.
- Restructuring charges of $227 million were recognized for enterprise-wide initiatives to modernize technology and improve operating efficiency.
- McKesson announced a definitive agreement to acquire a 70% controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures) for approximately $2.49 billion.
- The company returned $2.2 billion to shareholders through $2.0 billion in stock repurchases and $162 million in dividends during the first half of the fiscal year.
- The total estimated liability for opioid-related claims stands at $6.4 billion as of September 30, 2024.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2025, McKesson Corp kept $0.00.
- Revenue$93.65B100.0%
- Cost of revenue−$90.40B96.5%
- Gross profit$3.25B3.5%
- Operating costs−$2.67B2.9%
- Operating income$578.0M0.6%
- Interest, other & tax−$337.0M0.4%
- Net income$241.0M0.3%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2025filed November 7, 2024Financial Statements
Q2 FY2025 against Q2 FY2024
| Line item | Q2 FY2025Q2 FY2024 | Change |
|---|---|---|
| Revenue | $93.65B$77.22B | +21.3% |
| Cost of Revenue | $90.40B$74.15B | +21.9% |
| Gross Profit | $3.25B$3.07B | +5.8% |
| SG&A Expenses | $2.50B$2.09B | +19.6% |
| Operating Expenses | $2.67B$2.12B | +26.1% |
| Operating Income | $578.00M$951.00M | −39.2% |
| Interest Expense | $78.00M$61.00M | +27.9% |
| Net Income | $241.00M$664.00M | −63.7% |
| EPS (Basic) | $1.88$4.95 | −62.0% |
| EPS (Diluted) | $1.87$4.92 | −62.0% |
| Shares Outstanding (Basic) | 128.70M134.10M | −4.0% |
| Shares Outstanding (Diluted) | 129.30M134.80M | −4.1% |
05—Questions
Frequently Asked Questions
What is driving the significant increase in McKesson's revenues?
McKesson's revenue growth is primarily driven by market expansion in its U.S. Pharmaceutical segment, with higher volumes from retail national account customers and growth in specialty pharmaceuticals. International operations also contributed with increased pharmaceutical distribution volumes.
Why did diluted earnings per share decrease so significantly?
The decrease in diluted earnings per share is largely attributable to a substantial charge of $643 million related to the remeasurement of the Canadian retail disposal group to fair value less costs to sell. Additionally, restructuring charges totaling $227 million for technology modernization initiatives and higher overall operating expenses impacted profitability.
What is the status of the opioid-related litigation and its financial impact?
McKesson continues to face opioid-related litigation. The company has an estimated total liability of $6.4 billion as of September 30, 2024, which includes amounts for settlements with states, subdivisions, Native American tribes, acute care hospitals, and third-party payors. The company believes it has valid defenses for claims not covered by settlements.
How is McKesson returning capital to shareholders?
McKesson actively returns capital to shareholders through its share repurchase program and dividend payments. In the first half of fiscal year 2025, the company repurchased $2.0 billion of its common stock and paid $162 million in dividends. The quarterly dividend was also raised to $0.71 per share.
06—Continue